Citizens Reiterates Market Outperform on Structure Therapeutics, Maintains $110 Price Target

Citizens analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and maintains $110 price target.